P2, N=20, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Patients received cibisatamab with escalating doses of FAP-4-1BBL weekly or every 3 weeks after obinutuzumab pretreatment to mitigate anti-drug antibody formation. These findings demonstrate the feasibility of combining tumor antigen-directed T cell engagement with localized co-stimulation, with evidence of immune activation and preliminary antitumor activity supporting further clinical development. ClinicalTrials.gov identifier: NCT04826003 .

Treatment-emergent adverse events (TEAEs) led to treatment discontinuation in 16.0% of patients with CR; the most common TEAE was cytokine release syndrome (56.4%). This generally manageable safety profile and the sustainability of CRs support odronextamab as a potential long-term treatment for heavily pretreated R/R FL.

We report a case of minimal change disease presenting with AKI and nephrotic-range proteinuria 3 weeks after B-cell maturation antigen-directed CAR-T cell therapy, ciltacabtagene autoleucel, in a patient with relapsed refractory multiple myeloma. The patient received one dose of rituximab along with a short course of corticosteroid and had complete kidney recovery by week 4 of therapy. This report emphasizes the need for further investigation into the mechanism of kidney toxicity following CAR-T cell therapy, and potential benefits and risks of immunosuppressive therapy in this context.

P2, N=30, Active, not recruiting, Sun Yat-sen University

P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Mar 2026 --> Jun 2026

Even in the era of rituximab-based immunochemotherapy, survival benefits for these patients remain limited. In recent years, with the development of precision assessment tools such as genotyping and advances in research on personalized immunotargeted therapies, the understanding of CD5(+) DLBCL has deepened, offering the prospect of improved treatment outcomes for some patients. To further standardize diagnosis and treatment practices, the Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association and the Lymphoma Expert Committee of China Anti-Cancer Association have organized relevant experts to formulate this consensus, aiming to guide the standardized diagnosis and treatment of CD5(+) DLBCL patients in China.

P2, N=89, Completed, Heidelberg University | Active, not recruiting --> Completed

P1, N=30, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting

P2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

P2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

P1/2, N=41, Not yet recruiting, Fondazione Italiana Linfomi Ets